Tesaro Priced, Nasdaq: TSRO
Developing drugs for chemotherapy-induced nausea and solid tumors.
Industry: Health Care
First Day Return: +1.4%
TSRO
Developing drugs for chemotherapy-induced nausea and solid tumors.
| IPO Data | |
|---|---|
| IPO Date | 06/27/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $81 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Waltham, MA, United States |
| Founded | 2010 |
| Employees at IPO | 20 |
| Website www.tesarobio.com | |
IPO News for Tesaro
Tesaro (TSRO) Performance
